Literature DB >> 22172832

Preemptive kidney transplantation in systemic lupus erythematosus.

A Naveed1, C Nilubol, J K Melancon, R Girlanda, L Johnson, B Javaid.   

Abstract

Preemptive kidney transplantation is associated with superior outcomes. Patients who have kidney failure due to systemic lupus erythematosus (SLE) may not receive a preemptive kidney transplant because of the concern for risk of disease recurrence with shortened graft and patient survival. We identified 8001 patients in the United Network for Organ Sharing dataset who underwent kidney transplantation between October 1987 and February 2009 with kidney failure due to SLE. Seven hundred thirty patients received a preemptive kidney transplant with 7271 patients who were on dialysis before transplantation; their mean ages were 40.0±11.6 years and 36.9±11.7 years, respectively, (P<.01). Women constituted 82.5% of preemptive and 81.4% of non-preemptive groups (P=.47). Preemptive transplant recipients were more likely to receive a living donor kidney transplant (odds ratio [OR]=3.6; 95% confidence interval [CI]=3.3-4.5; P<.01). In unadjusted analyses, preemptive transplantation was associated with lower risk of recipient death (hazard ratio [HR]=0.52; 95% CI=0.38-0.70; P<.01). The difference remained significant after adjustment fr covariates (HR=0.55; 95% CI=0.36-0.84; P<.01). Graft survival was also superior among preemptive kidney transplant recipients in both unadjusted (HR=0.56; 95% CI=0.49-0.68; P<.01), and adjustment analyses (HR=0.69; 95% CI=0.55-0.86; P<.01). We concluded that preemptive kidney transplantation among patients with SLE was associated with superior patient and graft outcomes and should be considered when feasible.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22172832     DOI: 10.1016/j.transproceed.2011.08.092

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

Review 1.  Improving outcomes in patients with lupus and end-stage renal disease.

Authors:  Antonio Inda-Filho; Joel Neugarten; Chaim Putterman; Anna Broder
Journal:  Semin Dial       Date:  2013-09-04       Impact factor: 3.455

Review 2.  Kidney transplantation in patients with systemic lupus erythematosus.

Authors:  Sophia Lionaki; Chrysanthi Skalioti; John N Boletis
Journal:  World J Transplant       Date:  2014-09-24

3.  Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA.

Authors:  Michelle M O'Shaughnessy; Maria E Montez-Rath; Richard A Lafayette; Wolfgang C Winkelmayer
Journal:  Nephrol Dial Transplant       Date:  2015-11-25       Impact factor: 5.992

4.  Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Authors:  George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas
Journal:  Ann Rheum Dis       Date:  2012-07-31       Impact factor: 19.103

5.  Renal transplantation in systemic lupus erythematosus: outcome and prognostic factors in 50 cases from a single centre.

Authors:  Ernesto Cairoli; Carolina Sanchez-Marcos; Gerard Espinosa; Constanza Glucksmann; Guadalupe Ercilla; Federico Oppenheimer; Ricard Cervera
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

6.  Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis.

Authors:  Eleana Ntatsaki; Alba Velo-Garcia; Vassilios S Vassiliou; Alan D Salama; David A Isenberg
Journal:  Clin Rheumatol       Date:  2018-05-11       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.